Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q2 2026 · 10-Q
Revenue$103.55M$103.55M+20.1% vs Q2 2025 Net Income-$2.06M-$2.06MN/M vs Q2 2025 EPS Diluted-$0.07-$0.07N/M vs Q2 2025 Operating Income-$3,070,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$6,551,000−43.3% Margins · derivedOperating margin-3.0%+2.0 pt vs Q2 2025
Net margin-2.0%−7.2 pt vs Q2 2025
ended Jun 30, 2026 · filed Jul 30, 2026 · 30 d after period end